Obviously, the high cost of the therapy is news in and of itself, and it's very illustrative of the fact that high R&D costs need to be wrapped up in the cost o

Obviously, the high cost of the therapy is news in and of itself, and it's very illustrative of the fact that high R&D costs need to be wrapped up in the cost of the drug, even if the drug itself costs peanuts to make. (LITERAL PEANUTS, get it?!?) But what's more worrisome is that although oral immunotherapy appears to desensitize patients to the allergen, real-world evidence shows that these people actually end up experiencing allergic reactions more frequently than those who practice strict avoidance, the article reports. Whether that's because the patients who've undergone therapy are letting their guard down, or because the drug is only semi-protective, is unknown. But the article argues that the therapy might lead to a net increase, rather than a decrease, in allergic episodes.